Author

L. Wachsmuth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

D. Wilkinson· 2 shared P. E. Fecci· 2 shared X. Cui· 2 shared A. Hawley· 1 shared A. Hoyt-Miggelbrink· 1 shared A. Miggelbrink· 1 shared A. Mohan· 1 shared A. Patel· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. Wilkinson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Glioblastoma and other intracranial tumors elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses

S. J. Lorrey, L. Wachsmuth, J. Finlay, C. Neff, K. Ayasoufi, J. Waibl Polania, A. Hoyt-Miggelbrink, M. Price, L. Rein, S. Dell, R. Reesman, X. Cui, A. Hawley, E. Lerner, D. Wilkinson, , P. E. Fecci

This study shows that intracranial tumors cause systemic sympathetic hyperactivity, impairing T cell function and limiting immunotherapy, and that beta-adrenergic blockade improves outcomes in mouse models and human patients.

bioRxiv · Nov 2, 2023 · PreprintImmunology

A Novel MHC-Independent Mechanism of Tumor Cell Killing by CD8+ T Cells

E. C. Lerner, K. Woroniecka, V. D'Anniballe, D. Wilkinson, S. Lorrey, J. W. Polania, L. Wachsmuth, A. Miggelbrink, J. Raj, W. Tomaszewski, A. Mohan, X. Cui, M. Khasraw, M. D. Gunn, P. E. Fecci

This study shows CD8+ T cells can kill MHC-I-deficient tumor cells via NKG2D-NKG2DL interactions, independent of antigen recognition, and identifies this pathway as a potential therapeutic target.

bioRxiv · Feb 2, 2023 · PreprintImmunology